About Discoidin, CUB and LCCL domain-containing protein 2
Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a protein
from Homo sapiens identified by UniProt accession
Q96PD2, 775 residues long.
MolForge cross-references it against 0 known binders and
103 disease associations.
Target properties
| Protein name | Discoidin, CUB and LCCL domain-containing protein 2 |
| UniProt accession | Q96PD2 |
| Gene | DCBLD2 |
| Organism | Homo sapiens |
| Length | 775 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96PD2-F1 | alphafold | PREDICTED | 67.66 | — |
Amino-acid sequence (775 residues)
MASRAVVRAR RCPQCPQVRA AAAAPAWAAL PLSRSLPPCS NSSSFSMPLF LLLLLVLLLL LEDAGAQQGD GCGHTVLGPE SGTLTSINYP QTYPNSTVCE WEIRVKMGER VRIKFGDFDI EDSDSCHFNY LRIYNGIGVS RTEIGKYCGL GLQMNHSIES KGNEITLLFM SGIHVSGRGF LASYSVIDKQ DLITCLDTAS NFLEPEFSKY CPAGCLLPFA EISGTIPHGY RDSSPLCMAG VHAGVVSNTL GGQISVVISK GIPYYESSLA NNVTSVVGHL STSLFTFKTS GCYGTLGMES GVIADPQITA SSVLEWTDHT GQENSWKPKK ARLKKPGPPW AAFATDEYQW LQIDLNKEKK ITGIITTGST MVEHNYYVSA YRILYSDDGQ KWTVYREPGV EQDKIFQGNK DYHQDVRNNF LPPIIARFIR VNPTQWQQKI AMKMELLGCQ FIPKGRPPKL TQPPPPRNSN DLKNTTAPPK IAKGRAPKFT QPLQPRSSNE FPAQTEQTTA SPDIRNTTVT PNVTKDVALA AVLVPVLVMV LTTLILILVC AWHWRNRKKK TEGTYDLPYW DRAGWWKGMK QFLPAKAVDH EETPVRYSSS EVNHLSPREV TTVLQADSAE YAQPLVGGIV GTLHQRSTFK PEEGKEAGYA DLDPYNSPGQ EVYHAYAEPL PITGPEYATP IIMDMSGHPT TSVGQPSTST FKATGNQPPP LVGTYNTLLS RTDSCSSAQA QYDTPKAGKP GLPAPDELVY QVPQSTQEVS GAGRDGECDV FKEIL
Explore Discoidin, CUB and LCCL domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets